Pregledni rad
New Antipsychotics
Ljubomir Hotujac
Margita Rušinović
Stela Subotičanec
Sažetak
Antipsychotics that emerged on the market
after clozapine, synthesized on the basis of observed clinical
efficacy and pharmacological profile of clozapine activity, have
got various names: “newer antipsychotics”, “new antipsychotics”,
“atypical antipsychoitics” and “second generation
antipsychotics”. The name “second generation antipsychotics”
(SGA) is, according to all data, the most appropriate, so it has
become generally accepted when speaking about this heterogeneous
group of medications, which is clinically used for
almost identical indications. Reasons for such attitude lie in the
facts that it is questionable whether the distinction between typical
and atypical antipsychotics is scientifically justified. Furthermore,
all these drugs are not new (or newer) any more, and are
not pharmacologically and clinically identical, but have different
pharmacological and clinical efficacy. However, the fact remains
that they all belong to the second generation of antipsychotic
drugs. Here are described: amisulpride, clozapine, olanzapine,
quetiapine, risperidone, sertindole, ziprasidone, zotepine and
aripiprazole, up to now licensed in at least one country of the
European Union or in the USA, as well as iloperidone, which is
in the final phase of clinical research.
Ključne riječi
Hrčak ID:
19973
URI
Datum izdavanja:
25.9.2002.
Posjeta: 6.568 *